Clinical Sciences 2018
DOI: 10.1136/lupus-2018-lsm.68
|View full text |Cite
|
Sign up to set email alerts
|

CS-33 Performance of urinary HER2 as a biomarker of active proliferative lupus nephritis

Abstract: priorities. Disease burden can be measured using a variety of indicators such as mortality, morbidity or financial cost. For SLE, despite a relatively good 10 year survival (95%, vs 97% in controls), its mortality rate remains high relative to general population mortality rate as shown in our analysis of the Centers for Disease Control (CDC)'s mortality database comprising of 62,843 SLE deaths. However, mortality rates may not adequately measure SLE burden, because among those who died, a fifth of patients die… Show more

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles